![[CCO] Certification Coaching Organization LLC](https://staging.cco.us/wp-content/uploads/2015/05/CCO-Logo-2015-d3-500px.png "[CCO] Certification Coaching Organization LLC"){kind=logo}
🔍 Definition
Coagulation disorders encompass a broad spectrum of conditions characterized by abnormal hemostasis — either excessive bleeding (hemorrhagic disorders) or pathological clotting (thrombophilia/thrombotic disorders). The hemostatic process requires the coordinated interaction of platelets, the coagulation cascade (intrinsic, extrinsic, and common pathways), and natural anticoagulant systems (protein C, protein S, antithrombin III). Disruption at any point — whether congenital or acquired — produces clinically significant bleeding or thrombosis.
From a coding perspective, coagulation disorders span ICD-10-CM FY2026 category D65–D68 (coagulation defects), D69 (purpura and other hemorrhagic conditions), and D75.82 (heparin-induced thrombocytopenia). Accurate code assignment requires clinical documentation specifying etiology, severity, and relationship to other conditions — especially when anticoagulation therapy is involved.
Coagulation disorders are among the highest-impact diagnoses for HCC v28 Risk Adjustment. D65 (DIC), D66/D67 (Hemophilia A/B), and D68.x variants map to HCC 48 with an RAF weight of approximately 1.018 — one of the highest single-code RAF impacts in the hematology chapter. Failure to document and capture these codes can result in significant revenue leakage for MA plans.
🗂️ Alternative Terminology
Coagulation disorders are documented using a wide variety of clinical and lay terms. The table below maps common clinical terminology to the preferred ICD-10-CM indexable terms.
| Formal / ICD-10-CM Term | Alternative Clinical Names / Lay Terms |
|---|---|
| Disseminated intravascular coagulation (DIC) | Consumptive coagulopathy, defibrination syndrome, DIC syndrome, diffuse intravascular coagulation, microangiopathic coagulopathy |
| Hereditary Factor VIII deficiency (Hemophilia A) | Classic hemophilia, hemophilia A, Factor VIII deficiency, anti-hemophilic factor deficiency |
| Hereditary Factor IX deficiency (Hemophilia B) | Christmas disease, hemophilia B, plasma thromboplastin component deficiency, PTC deficiency |
| Von Willebrand disease (vWD) | vWD, vWF deficiency, von Willebrand factor deficiency, pseudo-hemophilia, angiohemophilia |
| Hereditary Factor XI deficiency (Hemophilia C) | Hemophilia C, Rosenthal syndrome, PTA deficiency, plasma thromboplastin antecedent deficiency |
| Acquired hemophilia | Factor VIII inhibitor, autoimmune hemophilia, acquired Factor VIII inhibitor, acquired coagulation inhibitor |
| Antiphospholipid syndrome (APS) | Hughes syndrome, lupus anticoagulant syndrome, anticardiolipin antibody syndrome, phospholipid antibody syndrome |
| Immune thrombocytopenic purpura (ITP) | Idiopathic thrombocytopenic purpura, immune thrombocytopenia, autoimmune thrombocytopenic purpura, Werlhof disease |
| Heparin-induced thrombocytopenia (HIT) | HIT type II, heparin-associated thrombocytopenia and thrombosis (HATT), white clot syndrome |
| Primary thrombophilia | Inherited thrombophilia, congenital hypercoagulable state, hereditary thrombotic disorder, Factor V Leiden, prothrombin gene mutation |
| Anticoagulant-associated hemorrhage | Warfarin toxicity/bleed, DOAC bleed, anticoagulant-related bleeding, over-anticoagulation, supratherapeutic INR |
🩺 Signs & Symptoms
Clinical presentation varies dramatically based on whether the disorder is hemorrhagic or thrombotic, and whether it is congenital or acquired.
Hemorrhagic Presentations
- Mucocutaneous bleeding: Petechiae, purpura, ecchymosis, mucosal bleeding, epistaxis — typical of platelet disorders (ITP, vWD type 1)
- Deep tissue bleeding: Hemarthrosis (joint bleeding), hematoma, compartment syndrome — typical of factor deficiencies (hemophilia A/B)
- Prolonged or excessive bleeding: Post-procedural/post-traumatic hemorrhage out of proportion to injury
- Spontaneous hemorrhage: Intracranial (I62.9), GI (K92.2), retroperitoneal — indicates severe coagulopathy
- DIC-specific: Simultaneous bleeding from multiple sites (IV sites, wounds, mucosa) plus end-organ signs of microthrombosis
Thrombotic Presentations
- Venous thromboembolism (VTE): DVT, PE — classic for APS, Factor V Leiden, prothrombin gene mutation
- Arterial thrombosis: Stroke (especially in APS), MI, peripheral arterial occlusion
- Microvascular thrombosis: Digital ischemia, livedo reticularis, Raynaud — seen in DIC, HIT, APS
- Recurrent pregnancy loss: Unexplained stillbirth, early fetal loss — strongly associated with APS
- HIT-specific: Paradoxical thrombosis (venous or arterial) despite or after heparin exposure + platelet count drop
Laboratory Abnormalities
- Elevated PT/INR: Extrinsic pathway defects, warfarin effect, liver disease, DIC, vitamin K deficiency
- Elevated PTT: Intrinsic pathway defects (hemophilia A/B/C), heparin effect, lupus anticoagulant, acquired inhibitors
- Thrombocytopenia: ITP, HIT, DIC, drug-induced, bone marrow failure
- Low fibrinogen: DIC (consumption), liver disease, dysfibrinogenemia
- Elevated D-dimer: Active fibrinolysis — sensitive but nonspecific; markedly elevated in DIC
- Low factor levels: Specific factor assays confirm hemophilia subtypes and acquired factor deficiencies
🧭 Differential Diagnosis
Distinguishing among coagulation disorders requires integration of clinical presentation, patient history, and laboratory data. The table below highlights key differentiating features for common coagulopathies.
| Condition | Key Differentiating Features | ICD-10-CM Code |
|---|---|---|
| DIC (Disseminated Intravascular Coagulation) | Underlying trigger (sepsis, OB, trauma, malignancy); simultaneous bleeding + clotting; ↑PT, ↑PTT, ↓fibrinogen, ↑D-dimer, ↓platelets; schistocytes on smear | D65 |
| Hemophilia A | Male; congenital; hemarthrosis/deep bleeds; ↑PTT, normal PT; low Factor VIII activity; family history | D66 |
| Hemophilia B (Christmas disease) | Male; congenital; similar to hemophilia A; normal Factor VIII, low Factor IX | D67 |
| Von Willebrand Disease | Most common inherited bleeding disorder; ↑PTT or normal; low vWF antigen/activity; mucocutaneous bleeding; both sexes | D68.0 |
| Hemophilia C (Factor XI deficiency) | Autosomal recessive; Ashkenazi Jewish population; mild-moderate; ↑PTT; low Factor XI | D68.1 |
| Acquired Hemophilia | Elderly or postpartum women; sudden-onset bleeds; ↑PTT; low Factor VIII, Factor VIII inhibitor present | D68.311 |
| Antiphospholipid Syndrome | Recurrent thrombosis and/or pregnancy loss; positive anticardiolipin Ab, anti-β2GP1, lupus anticoagulant; ↑PTT (paradoxically) | D68.61 |
| Factor V Leiden (Primary Thrombophilia) | Autosomal dominant; VTE risk; resistance to activated protein C; molecular testing confirms | D68.51 |
| ITP (Immune Thrombocytopenic Purpura) | Isolated thrombocytopenia; normal PT/PTT; anti-platelet antibodies; bone marrow shows megakaryocytes; no other cause | D69.3 |
| HIT (Heparin-Induced Thrombocytopenia) | Platelet drop >50% after heparin; 4T score ≥4; HIT-PF4 ELISA + SRA; paradoxical thrombosis; positive result confirms | D75.82 |
| Warfarin/DOAC-Induced Hemorrhage | Active anticoagulant therapy; elevated INR (warfarin) or anti-Xa level (DOACs); bleeding at drug-specific sites | D68.32 |
| Vitamin K Deficiency / Liver Disease | Malnutrition, malabsorption, hepatic failure; ↑PT/INR, ↑PTT; low multiple factors (II, VII, IX, X); responds to vit K | D68.4 |
| Drug-Induced Thrombocytopenia | Recent initiation of offending drug (heparin, quinidine, vancomycin); platelet recovery after drug cessation | D69.59 |
When a patient presents with thrombocytopenia after recent heparin exposure, query the provider to distinguish between HIT (D75.82), ITP (D69.3), and drug-induced thrombocytopenia (D69.59). Each has distinct treatment implications (HIT requires immediate heparin cessation + alternative anticoagulation) and different HCC/CC/MCC mapping. Documentation must support the 4T score criteria for HIT.
📋 Clinical Indicators for Coders/CDI
The following clinical indicators should be present in the medical record before assigning specific coagulation disorder codes. These are not exhaustive but represent minimum documentation standards aligned with CMS ICD-10-CM Official Guidelines FY2026.
| Condition | Required Clinical Indicators | Supporting Lab/Test Evidence |
|---|---|---|
| DIC (D65) | Active bleeding from ≥2 sites; clinical context (sepsis, trauma, OB emergency, malignancy, etc.); provider diagnosis of DIC | Platelet <100K + ↑PT/INR + fibrinogen <100 mg/dL + markedly ↑D-dimer; schistocytes optional but supportive; ISTH DIC score ≥5 |
| HIT (D75.82) | Heparin exposure (any form — IV, SQ, heparin flushes, LMWH); platelet drop >50% from baseline (or nadir <100K); provider diagnosis of HIT; thrombosis may or may not be present | 4T score ≥4 (intermediate/high pretest probability); HIT-PF4 antibody ELISA positive; serotonin release assay (SRA) gold standard; anti-PF4/heparin optical density >1.0 |
| ITP (D69.3) | Isolated thrombocytopenia (platelets typically <100K); provider rules out secondary causes; immune-mediated mechanism documented | Normal PT, PTT; anti-platelet antibodies (not always required); bone marrow normal or increased megakaryocytes; no other etiology identified |
| Acquired Hemophilia (D68.311) | Spontaneous bleeding without prior history; elderly or postpartum; no prior coagulopathy history; provider documents "acquired hemophilia" or "Factor VIII inhibitor" | Markedly ↑PTT not corrected by 1:1 mixing study; low/absent Factor VIII activity; Factor VIII inhibitor titer (Bethesda units) >0.5 BU |
| Anticoagulant Hemorrhage (D68.32) | Active anticoagulant therapy documented; provider links bleeding to anticoagulant effect; supratherapeutic levels or INR | Elevated INR (>3.0 for warfarin); elevated anti-Xa level for DOACs; site of hemorrhage documented (intracranial, GI, etc.) |
| APS (D68.61) | At least one clinical criterion (thrombosis or pregnancy morbidity) + at least one laboratory criterion (positive antiphospholipid antibody on 2 occasions ≥12 weeks apart) | Lupus anticoagulant; anti-cardiolipin IgG/IgM >40 GPL/MPL; anti-β2 glycoprotein-1 >99th percentile; Sapporo criteria met |
| Factor V Leiden / Prothrombin Gene Mutation (D68.51/D68.52) | Molecular testing confirming mutation; clinical context of thrombosis or screening in high-risk patient | Activated protein C resistance testing; factor V Leiden PCR; prothrombin gene 20210A mutation testing |
For D65 (DIC), the code is almost always a secondary diagnosis. Per ICD-10-CM Official Guidelines Section I.C.2, sequence the underlying condition first (e.g., A41.9 sepsis, O45.002 placental abruption with DIC, C80.1 malignancy). Code D65 as additional unless DIC itself is the reason for admission.
🦴 Anatomy & Pathophysiology
Understanding the coagulation cascade is essential for accurate code assignment and CDI query formulation. The hemostatic system operates in three phases:
Primary Hemostasis
Upon vascular injury, subendothelial collagen is exposed. Von Willebrand factor (vWF) bridges collagen to platelet GPIb receptors (adhesion), followed by platelet activation (shape change, granule release) and aggregation via GPIIb/IIIa receptors. Defects in vWF produce von Willebrand disease (D68.0).
Secondary Hemostasis (Coagulation Cascade)
Two pathways converge on the common pathway:
- Intrinsic pathway (contact activation): Factors XII → XI → IX → VIII → X. Measured by PTT. Defects in VIII (hemophilia A, D66), IX (hemophilia B, D67), or XI (hemophilia C, D68.1) prolong PTT without affecting PT.
- Extrinsic pathway (tissue factor pathway): TF-VIIa complex → Factor X. Measured by PT/INR. Vitamin K-dependent factor deficiencies (II, VII, IX, X) prolong PT — defects coded D68.2 or D68.4.
- Common pathway: Factor Xa + Va → prothrombin → thrombin → fibrinogen → fibrin clot. DIC (D65) represents dysregulated activation of this entire system.
Natural Anticoagulant Systems & Thrombophilia
Endogenous anticoagulants prevent pathological clotting: antithrombin III (ATIII) neutralizes thrombin and Xa; Protein C (activated by thrombomodulin-thrombin complex) inactivates Va and VIIIa; Protein S is a cofactor for activated protein C. Deficiency of any of these, or resistance to activated protein C (Factor V Leiden, D68.51), produces primary thrombophilia. Prothrombin gene mutation G20210A (D68.52) increases prothrombin levels and VTE risk.
Pathophysiology of DIC
DIC (D65) is characterized by uncontrolled systemic activation of coagulation triggered by underlying disease (sepsis, trauma, malignancy, obstetric emergency). Tissue factor released from damaged cells activates the extrinsic pathway systemically, generating massive thrombin → widespread microvascular thrombi (end-organ ischemia) + consumption of platelets, fibrinogen, and factors → simultaneous hemorrhage. The ISTH DIC scoring system (platelet count + fibrin markers + PT prolongation + fibrinogen) provides an objective basis for diagnosis.
Pathophysiology of HIT
HIT (D75.82) is an immune-mediated disorder in which heparin binds to platelet factor 4 (PF4), forming an antigenic complex that elicits IgG antibodies. These antibodies activate platelets via FcγRIIa receptors, generating procoagulant microparticles and causing paradoxical thrombocytopenia combined with a markedly elevated thrombotic risk. The 4T scoring system (Thrombocytopenia, Timing, Thrombosis, other causes) is the standard pretest probability tool.
💊 Medication Impact / Treatment
Medications are central to both the etiology and treatment of coagulation disorders. Accurate medication documentation directly affects code assignment (adverse effect vs. therapeutic use, sequencing of D68.32).
Anticoagulant Therapy (Long-Term Status Codes)
| Drug / Class | Long-Term Status Code | Mechanism | Monitoring |
|---|---|---|---|
| Warfarin (Coumadin) | Z79.01 | Vitamin K antagonist; inhibits factors II, VII, IX, X, protein C/S | PT/INR (target 2.0–3.0 most indications) |
| Apixaban, Dabigatran, Rivaroxaban, Edoxaban (NOACs/DOACs) | Z79.02 | Direct factor Xa or IIa (thrombin) inhibitors | Anti-Xa level (apixaban/rivaroxaban/edoxaban); Ecarin clotting time or diluted TT (dabigatran) |
| Aspirin (antiplatelet) | Z79.82 | COX-1 inhibitor; irreversible platelet thromboxane A2 inhibition | Platelet function assay (PFA-100, 85576) |
| Heparin (unfractionated) | Z79.02 or Z79.01 (per payer) | Antithrombin III potentiator; inhibits IIa and Xa | aPTT or anti-Xa (heparin anti-Xa, 85520) |
| LMWH (enoxaparin, dalteparin) | Z79.02 | Primarily anti-Xa activity; some anti-IIa | Anti-Xa level (peak 4h post SQ dose); renal dose adjustment |
Adverse Effect Coding for Anticoagulants
When a patient on anticoagulation develops hemorrhage due to the pharmacologic effect of the drug (even at therapeutic doses), code as adverse effect:
- T45.51xA — Adverse effect of anticoagulants, initial encounter (patient taking drug correctly)
- T45.516A — Underdosing of anticoagulants, initial encounter (patient took less than prescribed — rare cause of thrombosis)
- T45.511A — Poisoning by anticoagulants, accidental (unintentional), initial encounter
Sequencing for anticoagulant-induced hemorrhage: code the site of hemorrhage first, followed by D68.32, then T45.51xA, then Z79.01 or Z79.02 for long-term use status.
Factor Replacement & Hemostatic Agents
- Factor VIII concentrates (J7190–J7192, recombinant J7209–J7211): Hemophilia A and acquired hemophilia
- Factor IX concentrates (J7193–J7195): Hemophilia B
- vWF concentrate (J7184): Type 3 vWD and severe Type 1/2
- Recombinant Factor VIIa (J7212): Hemophilia with inhibitors, acquired hemophilia
- 4-Factor PCC (Kcentra): Warfarin reversal; urgent surgery; Q-code or J-code per payer
- Andexanet alfa (Andexxa/J7169): Direct reversal of Factor Xa inhibitors (apixaban, rivaroxaban)
- Idarucizumab (Praxbind): Dabigatran reversal; J-code or unclassified per payer
- Phytonadione / Vitamin K (J3430): Warfarin reversal, vitamin K deficiency (D68.4)
HIT Treatment
Immediate heparin cessation (all forms) + alternative anticoagulation with direct thrombin inhibitors (argatroban, bivalirudin) or fondaparinux (J1652 Arixtra). LMWH is contraindicated in acute HIT due to cross-reactivity. Warfarin should not be initiated until platelet count recovers to >150K.
Preview ends here. The full guide continues with FY2026 ICD-10-CM code sets, CPT surgical coding, MS-DRG mapping, reimbursement guidance, CDI query templates, and an audit checklist — all available to CCO Members.
← Back to All Clinical Documentation Guides
🔒 Register or sign in to read the full guide
Unlock the full guide including:
- • 📘 ICD-10-CM Guidelines (FY2026)
- • 🔢 ICD-10-CM Code Set (FY2026)
- • 🔎 Indexing
- • 🏥 CPT (2026)
- • 🧾 HCPCS (2026)
- • 📚 AHA Coding Clinic (Recent Guidance)
- • 💰 HCC / Risk Adjustment (v28)
- • ✍️ CDI Query Templates
- • 🧑⚕️ Treatments (Clinical)
- • 🎓 Patient Education / Summary
